2013
DOI: 10.1089/nat.2013.0443
|View full text |Cite
|
Sign up to set email alerts
|

Characterization of Target mRNA Reduction Through In Situ RNA Hybridization in Multiple Organ Systems Following Systemic Antisense Treatment in Animals

Abstract: Advances in the medicinal chemistry of antisense oligonucleotide drugs have been instrumental in achieving and optimizing antisense activity in cell types other than hepatocytes, the cell type that is most sensitive to antisense effects following systemic treatment. To broadly characterize the effects of antisense drugs on target messenger RNA (mRNA) levels in different organs and cell types in animals, we have developed a sensitive RNA in situ hybridization technique using the noncoding RNA metastasis associa… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
107
0

Year Published

2014
2014
2022
2022

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 112 publications
(110 citation statements)
references
References 22 publications
3
107
0
Order By: Relevance
“…These ASO reduced Lxr␣ 40 -90% in multiple tissues, including liver, white adipose tissue, kidney, spleen, and heart (data not shown), consistent with prior literature (27).…”
Section: Resultssupporting
confidence: 90%
“…These ASO reduced Lxr␣ 40 -90% in multiple tissues, including liver, white adipose tissue, kidney, spleen, and heart (data not shown), consistent with prior literature (27).…”
Section: Resultssupporting
confidence: 90%
“…ASOs are currently in clinical trials for many diseases, including spinal muscular atrophy and Duchenne muscular dystrophy (Aartsma-Rus et al 2004;Rigo et al 2012). The in vivo efficacies of Malat1 ASOs have been tested in primates, where >80% knockdown efficiency was achieved (Koller et al 2011;Hung et al 2013). Here we show that Malat1 knockdown results in slower tumor proliferation and differentiation and significant reduction in metastasis, all recapitulating the phenotype of the MMTV-PyMT; Malat1…”
Section: Malat1 Asos Are a Promising Therapeuticmentioning
confidence: 99%
“…When oligonucleotides, such as 2¢-O-methoxyethyl phosphorothioates, are systemically delivered in vivo, they reach many tissues and cell types but predominantly the liver [102]. However, uptake by itself is not sufficient for an effective cleavage of the target RNA.…”
Section: Uptakementioning
confidence: 99%